Symbol="AFMD"
AssetType="Common Stock"
Name="Affimed NV"
Description="Affimed NV, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company is headquartered in Heidelberg, Germany."
CIK="1608390"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="IM NEUENHEIMER FELD 582, 69120, HEIDELBERG, DE"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="89603000"
EBITDA="-101675000"
PERatio="None"
PEGRatio="0"
BookValue="0.838"
DividendPerShare="0"
DividendYield="0"
EPS="-0.73"
RevenuePerShareTTM="0.265"
ProfitMargin="-2.565"
OperatingMarginTTM="-2.591"
ReturnOnAssetsTTM="-0.354"
ReturnOnEquityTTM="-0.836"
RevenueTTM="39499000"
GrossProfitTTM="41801000"
DilutedEPSTTM="-0.73"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.407"
AnalystTargetPrice="6.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.796"
PriceToBookRatio="0.923"
EVToRevenue="2.199"
EVToEBITDA="0.533"
Beta="2.354"
num_52WeekHigh="3.4"
num_52WeekLow="0.52"
num_50DayMovingAverage="0.723"
num_200DayMovingAverage="1.121"
SharesOutstanding="149339000"
DividendDate="None"
ExDividendDate="None"
symbol="AFMD"
open="0.63"
high="0.63"
low="0.56"
price="0.57"
volume="389257.00"
latest_trading_day="2023-07-27"
previous_close="0.61"
change="-0.04"
change_percent="-7.1964%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="78"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="22"
Volume_recent_avg="946038"
Change_recent_avg="-0.01"
Delta_recent_avg="0.07"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-1.2"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="22"
Aroon_momentum_negative="78"
image_negative_thumbnail_id_1="1134"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0167.jpeg"
image_negative_thumbnail_id_2="502"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0103.jpeg"
image_neutral_thumbnail_id_1="573"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0026.jpeg"
image_neutral_thumbnail_id_2="570"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0029.jpeg"
image_positive_thumbnail_id_1="703"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0005.jpeg"
image_positive_thumbnail_id_2="965"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0127.jpeg"
image_professor_thumbnail_id_1="1180"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
image_professor_thumbnail_id_2="1202"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
